Weight Loss Injections and Heart Failure: What the Research Actually Shows

What the STEP-HFpEF trial found (and why the type of heart failure matters

In 2023, the STEP-HFpEF trial enrolled 529 adults with obesity and heart failure with preserved ejection fraction) the form in which the heart's pumping chambers remain largely intact but the heart stiffens and fills poorly. Participants received either semaglutide 2.4mg weekly or placebo for 52 weeks alongside usual care. Those on semaglutide lost around 13% of body weight on average; they also scored significantly better on a composite of symptoms, physical limitations and six-minute walk distance. The placebo group saw far smaller changes on all three measures.

This matters because HFpEF is strongly tied to excess weight. Adipose tissue drives inflammation, raises cardiac filling pressures and worsens the structural stiffening that underlies the condition. Reducing that load appears to translate into real functional gains, not just a better number on the scales. The NHS medicines page for semaglutide provides an accessible overview of how the drug works and what to expect.

Heart failure with reduced ejection fraction (HFrEF) is a meaningfully different condition: the pumping function is impaired, not just the filling. Earlier data from liraglutide in HFrEF raised signals of increased heart rate and no clinical benefit, and neither tirzepatide nor semaglutide is currently recommended in this group outside specialist evaluation. Anyone with an HFrEF diagnosis should discuss GLP-1 medicines explicitly with their cardiologist before considering them. The question of whether weight loss injections are appropriate with a heart failure diagnosis really does hinge on which type you have.

What the cardiovascular evidence says beyond HFpEF

The picture across cardiac conditions is broader than a single heart failure trial. Wegovy (semaglutide 2.4mg) holds a UK licence specifically for reducing the risk of major cardiovascular events (heart attack and stroke) in eligible adults with established cardiovascular disease and obesity. That authorisation followed the SELECT trial, which showed a 20% relative reduction in major cardiovascular events over roughly five years. The SELECT population included people with coronary artery disease, peripheral arterial disease and stroke history, though it was not specifically a heart failure population.

For those with coexisting heart disease and obesity, the relationship between weight loss injections and heart disease more broadly is worth understanding before any consultation. Tirzepatide cardiovascular outcomes data is accumulating in the SURPASS-CVOT programme; results are expected to clarify its profile further. What is already clear from NICE's appraisal of tirzepatide (TA1026) is that the clinical reviewers considered the cardiovascular comorbidity context carefully — dyslipidaemia and hypertension both appear on the qualifying conditions list for NHS prescribing.

A prescriber assessing someone with cardiac history will look at your ejection fraction, current medications, any arrhythmia, and how well your condition is controlled before forming a view. That is a clinical judgement, not a checkbox. It is also one reason guidance for heart patients considering weight loss injections consistently points toward specialist review as the first step.

Practical considerations: medications, monitoring and routine

People with heart failure are often on several medicines, diuretics, ACE inhibitors, beta-blockers, mineralocorticoid antagonists, SGLT2 inhibitors. GLP-1 medicines do not directly interact with most of these, but the clinical picture is still relevant. If GI side effects cause reduced fluid intake, and you are also on a loop diuretic, your electrolytes and kidney function may need closer monitoring during the early weeks of treatment. Your prescriber and GP both need to know you are starting a GLP-1 medicine.

One practical point our prescribers hear fairly often: the pen lives in the fridge, and people with heart failure are sometimes managing multiple conditions that mean the medicine cabinet is already busy. Keeping the pen on the same shelf, taken out once a week at the same time, reduces the chance of a missed dose. Storage and technique questions are covered in the guide to self-injections for weight loss.

For anyone with a cardiac condition, GP notification is standard practice at nume regardless of the clinical picture. Our clinical team follows GPhC guidance on GP communication, and our prescribers flag cardiac history explicitly when writing to your GP. Keeping your whole clinical team informed matters more here than on most other treatment pages. You can see a full overview of the weight loss injections available through nume, and if cost is a factor, a plain-language rundown of what weight loss injections cost in the UK covers what legitimate pricing includes.

What clinical assessment looks like when heart failure is in your history

The licensed eligibility for tirzepatide and semaglutide is straightforward on paper: adult, BMI 30 or above (or 27 or above with a qualifying condition), not pregnant, no contraindications. Heart failure is not an automatic contraindication, but it is a red flag that requires a more detailed assessment than a straightforward obesity case.

At nume, the consultation is reviewed the same day by a GPhC-registered independent prescriber, a real clinician reads your answers, not an automated pathway. When a cardiac condition is declared, the prescriber considers the type of heart failure, current control, existing medicines, and whether specialist input is needed before proceeding. Transfer patients with an existing cardiac diagnosis may be asked to provide documentation of their current treatment plan. That is not bureaucracy for its own sake; it is how responsible prescribing of a prescription-only medicine works.

For people with a heart condition of any kind considering weight loss injections, an honest conversation with both your cardiologist and a prescribing pharmacist is the most useful starting point. If you would like a prescriber at nume to review your situation, check your eligibility through our free consultation, there is no commitment, and you will get a clear clinical answer.